An Open-label Study in Healthy Participants to Evaluate AZD0780 as an Object or Precipitant of CYP3A4-mediated Drug-drug Interactions
An Open-label Study in Healthy Participants to Assess the Pharmacokinetics of AZD0780 When Administered Alone and in Combination With Itraconazole or Carbamazepine, and to Assess the Pharmacokinetics of Midazolam, and Ethinyl Estradiol/Levonorgestrel When Administered Alone and in Combination With AZD0780
Sponsor: AstraZeneca
Listed as NCT06671405, this PHASE1 trial focuses on Dyslipidaemia and remains completed. Sponsored by AstraZeneca, it has been updated 4 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
4 versions recorded-
May 2025 — Present [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE1
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE1
-
Dec 2024 — Mar 2025 [monthly]
Recruiting PHASE1
First recorded
Sep 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .